Researchers working on a vaccine for the novel coronavirus have announced promising results in a very small drug trial.
Biotech company Moderna said the first phase of trials for a COVID-19 vaccine was tested on 45 human volunteers.
Early data shows eight of the volunteers developed a type of...
Despite vaccines in development, the head of the World Health Organization cautioned that the treatments had yet to prove effective and might only convey protection for a short time. This report produced by Zachary Goelman.
The Government has announced two new tests for coronavirus and flu, which canreturn results in just 90 minutes, are to be deployed in hospitals, care homesand laboratories from next week. The tests have been hailed as a crucialinstrument in the fight against the pandemic, especially as the UK heads intothe colder months. There are two types of test; the swab test and the finger-prick test, used to test if a person has Covid-19 or once had the virus. Thetwo current test available has some setbacks, mainly being the amount of timeit takes to process results, between 24-72 hours to get results. The mainthing with the news test, yet to be introduced, is the speed with which theyare able to detect not just Covid-19, but also other seasonal illnesses. Thiswill be crucial as Britain heads into winter, as will easily identify ifsufferers will need to self-isolate.
Credit: PA - Press Association STUDIO Duration: 02:30Published
A coronavirus vaccine developed by CanSino Biologics Inc appears to be safe. It induced a rapid immune response in its first human trial, Reuters reports. This vaccine did not cause any serious adverse..
AstraZeneca expects to be able to deliver a billion doses of a possible COVID-19 vaccine this year and next if tests are successful, adding on Thursday it should shortly get results of an early stage..
The S&P 500 closed lower on Tuesday, as investors focused on a report questioning Moderna's recent coronavirus vaccine early-stage trial results, wiping out... Newsmax Also reported by •NPR •Seattle Times